EP0543968A1 - 3-ARYL- OU 3-HETARYL-$g(b)-CARBOLINES, LEUR FABRICATION ET LEUR UTILISATION DANS DES MEDICAMENTS - Google Patents

3-ARYL- OU 3-HETARYL-$g(b)-CARBOLINES, LEUR FABRICATION ET LEUR UTILISATION DANS DES MEDICAMENTS

Info

Publication number
EP0543968A1
EP0543968A1 EP92912055A EP92912055A EP0543968A1 EP 0543968 A1 EP0543968 A1 EP 0543968A1 EP 92912055 A EP92912055 A EP 92912055A EP 92912055 A EP92912055 A EP 92912055A EP 0543968 A1 EP0543968 A1 EP 0543968A1
Authority
EP
European Patent Office
Prior art keywords
methoxymethyl
carboline
benzyloxy
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92912055A
Other languages
German (de)
English (en)
Inventor
Andreas Huth
Dieter Seidelmann
Ralph Schmiechen
Herbert Schneider
Lechoslaw Turski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of EP0543968A1 publication Critical patent/EP0543968A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Definitions

  • the invention relates to new 3-hetaryl and 3-aryl-ß-carbolines, their preparation and use in medicaments.
  • 3-position substituted ⁇ -carbolines according to the invention are bioavailable over a longer period of time and at the same time have a good affinity for the benzodiazepine receptors.
  • the compounds according to the invention have the formula I.
  • R A is halogen, -CHR 1 -R 2 , optionally substituted with halogen, C 1-4 alkoxy or amino, phenyl, hetaryl or OR 5 and can be one to two times and
  • R 1 is hydrogen or C 1-4 alkyl
  • R 2 is hydrogen, C 1-4 alkyl, -OC 1-4 alkyl or an optionally substituted phenyl, benzyl or phenoxy radical and
  • R represents hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl or an optionally substituted phenyl, benzyl, hetaryl or benzo-fused hetaryl radical,
  • Hydrogen, C 1-4 alkyl or C 1-4 alkoxy-C 1-4 alkyl and R 3 is a C 6-12 aryl optionally substituted one or more times with C 1-4 alkyl, C 1-4 cycloalkyl, halogen, C 1-4 alkoxyC 1-4 alkyl, phenyl or amino. or hetaryl radical, and their isomers and acid addition salts.
  • the substituent R A can be in the A-ring in position 5-8, preferably in the 5-, 6- or 7-position.
  • Alkyl contains both straight and branched chain residues such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec. Butyl, tert. Butyl, pentyl, isopentyl and hexyl.
  • Halogen is to be understood as fluorine, chlorine, bromine and iodine.
  • Cycloalkyl can each represent cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and 2-methylcyclopropyl, 3-5 carbon atoms being preferred.
  • R 5 or R A is a hetaryl radical, this is 5- or 6-membered and contains 1-3 heteroatoms such as nitrogen, oxygen and / or sulfur.
  • the following 5- and 6-ring heteroaromatics may be mentioned: pyridm, pyrimidine, pyrazine, pyridazine. Furan, thiophene, pyrrole, thiazole, imidazole, triazine.
  • R 5 is a benzo-condensed hetaryl radical, this preferably contains 1-2 nitrogen atoms such as quinoline, isoquinoline, quinoxaline or benzimidazole.
  • the substituent of the phenyl, benzyl, hetaryl and benzo-fused hetaryl radical R 5 can be one to three times in any position.
  • Suitable substituents are halogens, nitro, cyano, C 1-4 alkyl, C 1-4 alkoxy, amino, C1-4 alkoxycarbonyl, C 1-4 alkylthio and trifluoromethyl, the mono- and benzyl radicals being the mono- up to two
  • Preferred hetaryl radicals and benzo-fused hetaryl radicals R 5 are nitrogen-containing heterocycles which are substituted one to two times with halogen, C 1-4 -alkyl, C 1-4 -alkoxy or trifluoromethyl, in particular with halogen.
  • Suitable substituents for the phenyl, benzyl and phenoxy radical R 2 are the aromatic substituents mentioned for R 5 , in particular halogen such as chlorine and bromine.
  • the aryl and hetaryl radical R 3 can be present as a mono- or bicyclic and
  • 5-12 ring atoms preferably 5-9 ring atoms, contain such as
  • Heteroatoms such as sulfur, oxygen and / or nitrogen.
  • the substituent of the aryl and hetaryl radical R 3 can be one to three, in particular simple.
  • R A in the meaning of OR 5 , where R 5 is C 1-6 alkyl, or an optionally mono- or disubstituted phenyl or benzyl radical or a five- or six-membered optionally benzo-fused heterocycle with 1 -3 nitrogen atoms, which is optionally mono- or disubstituted, and R 3 is phenyl which is optionally substituted by halogen or C 1-4 -alkoxy or by an optionally substituted five- or six-membered heterocycle with 1-3 heteroatoms such as 1,3,4-oxadiazol-2-yl, thienyl, pyrrolyl, pyridyl, thiazolyl, oxazolyl or a benzo-fused heterocycle such as benzothienyl.
  • C 1-4 alkyl and phenyl are to be regarded as preferred and as a substituent of the 1,3,4-oxadiazolyl radical is C 1-4 alkyl, C 1-4 alkoxy-C 1- 2- alkyl, C 3-7 cyclopropyl and amino preferred.
  • the compounds of the formula I can be in the form of the stereoisomers and mixtures thereof.
  • the physiologically compatible acid addition salts are derived from the known inorganic and organic acids such as, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, formic acid, acetic acid, benzoic acid, maleic acid, fumaric acid, succinic acid, tartaric acid, citric acid, oxalic acid, glyoxylic acid and arylsulfonic acids and, for example, such as alkanesulfonic acid and arylsulfonic acids Methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and others
  • the compounds of the formula I and their acid addition salts can be used as medicaments and exert antagonistic, inverse agonistic and agonistic effects on the properties known from benzodiazepines.
  • the compounds according to the invention have an extended duration of action and are distinguished by anxiolytic activity.
  • the affinity for the benzodiazepine receptors is determined by examining the displacement capacity of rakio-labeled flunitrazepam by the benzodiazepine receptors.
  • the compounds are tested in a 4-plate test using the method of Boissier et al Eur. J. Pharmacol. 4, 145-150 (19S8) tested.
  • the minimum, lowest dose (MED) is given, which determines the locomotor activity of the punished mice after i.p. Treatment increased.
  • a decrease in activity in the 4-plate test without punishment indicates sedative properties.
  • the compounds of formula I are particularly suitable for the treatment of anxiety accompanied by depression and sleep disorders.
  • the compounds according to the invention are brought into the form of a pharmaceutical preparation which, in addition to the active ingredient for enteral or parenteral administration, has suitable pharmaceutical, organic or inorganic inert carrier materials, such as water, gelatin, gum arabic, milk sugar, starch, Contains magnesium stearate, talc, vegetable oils, polyalkylene glycols etc.
  • suitable pharmaceutical, organic or inorganic inert carrier materials such as water, gelatin, gum arabic, milk sugar, starch, Contains magnesium stearate, talc, vegetable oils, polyalkylene glycols etc.
  • the pharmaceutical preparations can be in solid form, for example as tablets, dragées, suppositories, capsules or in liquid form, for example as solutions, suspensions or emulsions. If necessary, they also contain auxiliary substances such as preservatives, stabilizers, wetting agents or emulsifiers, salts for changing the osmotic pressure or buffers.
  • Injection solutions or suspensions in particular aqueous solutions of the active compounds in polyhydroxyethoxylated castor oil, are particularly suitable for parenteral use.
  • Surface-active auxiliaries such as salts of bile acids or animal or vegetable phospholipids, but also mixtures thereof and liposomes or their components can also be used as carrier systems.
  • tablets coated tablets or capsules with talc and / or hydrocarbon carriers or binders, such as
  • Example lactose corn or potato starch, suitable. It can also be used in liquid form, for example as juice, to which a sweetener may be added.
  • the compounds according to the invention are introduced in a dose unit of 0.05 to 100 mg of active substance in a physiologically compatible carrier.
  • the compounds according to the invention are generally used in a dose of 0.1 to 300 mg / day, preferably 0.1 to 30 mg / day, particularly preferably 1-20 mg / day, for example as anxiolytics analogous to diazepam.
  • the compounds according to the invention are prepared by processes known per se.
  • the compounds of the formula I are obtained by a) a compound of the formula II
  • R A and R 4 have the above meaning and Hal is halogen, in the presence of a nickel or palladium catalyst with an organometallic
  • R 3 has the above meaning
  • X is halogen, hydroxy or C 1-4 alkyl
  • n 1 to 3
  • arylated or b) a compound of formula IV
  • R A and R 4 have the above meaning, with orthocarboxylic acid esters cyclized to compounds of formula I with R 3 in the meaning of a
  • R A and R 4 have the meaning given above, Z is halogen and R 9 represents hydrogen or a protective group, cyclized with thiocarboxamides to give compounds of the formula I with R 3 meaning an optionally in
  • R A and R 4 have the above meaning with tosyl methyl isocyanide in the presence of bases cyclized to compounds of the formula I with R 3 in the meaning of an oxazol-5-yl radical and, if desired, subsequently splitting off the benzyl group R 5 or R A in the meaning of Hydroxy etherifies or separates the isomers or forms the acid addition salts.
  • the arylation according to process variant a) takes place in solution or in suspension in inert solvents at temperatures from 0 ° C. to the boiling point of the reaction mixture.
  • Suitable solvents are, for example, cyclic and acyclic ethers such as diethyl ether, tetrahydrofuran and dioxane, hydrocarbons such as toluene and benzene and aprotic, polar solvents such as dimethylformamide, dimethylacetamide, N-methylpyrrolidone, etc.
  • cyclic and acyclic ethers such as diethyl ether, tetrahydrofuran and dioxane
  • hydrocarbons such as toluene and benzene and aprotic
  • polar solvents such as dimethylformamide, dimethylacetamide, N-methylpyrrolidone, etc.
  • protic solvents such as e.g. Alcohol nothing.
  • bromine and iodine come into consideration as halogen hal.
  • the organometallic compound of the general formula III contain lithium, magnesium, zinc, tin or boron as the metal atom, where the substituent X can in each case be one to three times depending on the valence of the metal atom and X is halogen, in particular chlorine or bromine.
  • Suitable nickel and palladium catalysts are, for example, 1,3-diphenylphosphinopropane-nickel-II-chloride, bis-tri-o-tolylphosphine-palladium-II-chloride, bis-triphenylphosphine-palladium-II-chloride, tetrakis-triphenylphosphine -palladium- (0) and 1,1'-bis-diphenylphosphinoferrocenpal- ladium-II-chloride.
  • 1,3,4-Oxadiazoles are prepared by process variant b) by heating ⁇ -carboline-3-carboxylic acid hydrazides with orthocarboxylic acid esters in solution or in suspension and subsequent cyclization in the presence of a base such as, for example, alkali metal alcoholates such as sodium or potassium ethylate, -ter. butylate.
  • a base such as, for example, alkali metal alcoholates such as sodium or potassium ethylate, -ter. butylate.
  • the corresponding alcohols are suitable as solvents.
  • the reaction takes place at temperatures up to the boiling point of the reaction mixture and is complete after about 2-10 hours.
  • Any protective groups present in the 9-position of the ⁇ -carboline can be treated with the customary methods, such as treatment with bases, for example alkali alcoholate or hydroxide or acids such as dilute mineral acid or with fluorides such as casium fluoride be split off at room temperature or elevated temperature.
  • bases for example alkali alcoholate or hydroxide or acids such as dilute mineral acid or with fluorides such as casium fluoride be split off at room temperature or elevated temperature.
  • fluorides such as casium fluoride be split off at room temperature or elevated temperature.
  • 3-carbaldehyde- ⁇ -carbolines of the formula VI are reacted with tosylmethyl isocyanide in suspension or in solution.
  • the reaction takes place in the presence of bases such as alkali carbonates or alkali alcoholates in protic solvents such as alcohols at temperatures up to the boiling point of the reaction mixture and is complete after about 1-3 hours. If the removal of the radical R 5 is desired, this is done according to the in
  • EP-A-130 140 described methods or by hydrogenolytic
  • the subsequent subsequent etherification of the free hydoxy group is carried out by the process described in EP-A-237 467, in which the reactive compound R A -Y, in which Y is, for example, halogen, tosylate, mesylate or triflate, in the presence of a base such as alkali alcoholate or hydroxide in polar solvents such as dimethyl sulfoxide, dimethylformamide, acetonitrile or alcohols is reacted at room temperature or elevated temperature, if appropriate in the presence of phase transfer catalysts.
  • a base such as alkali alcoholate or hydroxide
  • polar solvents such as dimethyl sulfoxide, dimethylformamide, acetonitrile or alcohols
  • the isomer mixtures can be separated into the diastereomers or enantiomers by customary methods such as, for example, crystallization, chromatography or salt formation.
  • a compound of the formula I is dissolved, for example, in a little alcohol and mixed with a concentrated solution of the desired acid.
  • the compounds of the formula IV are prepared by heating the ß-carboline-3-carboxylic acid alkyl ester with hydrazine hydrate.
  • 6-Benzyloxy-4-methoxymethyl-ß-carboline-3-carboxylic acid is prepared according to the process given in EP-A-161 574 from 6-benzyloxy-4-methoxymethyl-ß-carboline-3-carboxylic acid isopropyl ester.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Il est décrit des composés de formule (I), dans laquelle R3 désigne un reste aryle ou hétaryle en C6-12 substitué le cas échéant une ou plusieurs fois par un alkyle en C1-4, un cycloalkyle en C3-7, un halogène, un alkoxy-C1-4-alkyl-C1-2, un phényle ou un amino, le procédé de fabrication de ces composés, ainsi que leur utilisation dans des médicaments.
EP92912055A 1991-06-15 1992-06-12 3-ARYL- OU 3-HETARYL-$g(b)-CARBOLINES, LEUR FABRICATION ET LEUR UTILISATION DANS DES MEDICAMENTS Withdrawn EP0543968A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4120109 1991-06-15
DE4120109A DE4120109A1 (de) 1991-06-15 1991-06-15 3-aryl- oder 3-hetaryl-(beta)-carboline, deren herstellung und verwendung in arzneimitteln

Publications (1)

Publication Number Publication Date
EP0543968A1 true EP0543968A1 (fr) 1993-06-02

Family

ID=6434220

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92912055A Withdrawn EP0543968A1 (fr) 1991-06-15 1992-06-12 3-ARYL- OU 3-HETARYL-$g(b)-CARBOLINES, LEUR FABRICATION ET LEUR UTILISATION DANS DES MEDICAMENTS

Country Status (6)

Country Link
EP (1) EP0543968A1 (fr)
JP (1) JPH06501956A (fr)
CA (1) CA2089569A1 (fr)
DE (1) DE4120109A1 (fr)
PT (1) PT100593A (fr)
WO (1) WO1992022549A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4330175A1 (de) * 1993-08-31 1995-03-02 Schering Ag Alkoxy-substituierte beta-Carboline
EP1134221A1 (fr) * 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Bêta-carbolines substituées comme inhibiteurs de lkB kinase

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57123180A (en) * 1980-12-17 1982-07-31 Schering Ag 3-substituted beta-carboline, manufacture and psychotropic drug containing same
DE3240511A1 (de) * 1982-10-29 1984-05-03 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur herstellung von ss-carbolinderivaten
DE3322895A1 (de) * 1983-06-23 1985-01-03 Schering AG, 1000 Berlin und 4709 Bergkamen Neue ss-carboline, verfahren zur ihrer herstellung und ihre verwendung als arzneimittel (s)
DK240084D0 (da) * 1984-05-15 1984-05-15 Ferrosan As New beta-carboline-3-oxadiazolyl derivatives
DE3540654A1 (de) * 1985-11-13 1987-05-14 Schering Ag Phenoxy-substituierte ss-carbolinderivate, ihre herstellung und ihre verwendung als arzneimittel
DE3608089A1 (de) * 1986-03-08 1987-09-10 Schering Ag Heteroaryl-oxy-ss-carbolinderivate, ihre herstellung und ihre verwendung als arzneimittel
AU619203B2 (en) * 1987-08-28 1992-01-23 Schering Aktiengesellschaft Isoxazole-beta-carboline derivatives
DE3903753A1 (de) * 1989-02-06 1990-08-23 Schering Ag Verfahren zur herstellung waessriger mischmicelloesungen
DE3943225A1 (de) * 1989-12-23 1991-06-27 Schering Ag Neue ss-carboline, verfahren zu deren herstellung und deren verwendung in arzneimitteln

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9222549A1 *

Also Published As

Publication number Publication date
PT100593A (pt) 1993-08-31
DE4120109A1 (de) 1992-12-17
JPH06501956A (ja) 1994-03-03
CA2089569A1 (fr) 1992-12-16
WO1992022549A1 (fr) 1992-12-23

Similar Documents

Publication Publication Date Title
EP0450566B1 (fr) Azoles substitués, procédés pour leur préparation, compositions les contenant et leur utilisation
EP0275888B1 (fr) Benzimidazoles tricycliques, leur procédé de préparation et utilisation comme médicament
EP0150040B1 (fr) Dérivés de imidazobenzodiazépine
EP0973774B1 (fr) Derives de 1,5-dihydro-pyrazolo 3,4-d]-pyrimidinone
DE10327439A1 (de) Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
EP0533058A1 (fr) Iso- et hétérocycles imidazo-condensés comme antagonistes d'angiotensine II
DE3935514A1 (de) Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0468372A2 (fr) Azoles substitués, procédé pour leur préparation et leur utilisation
EP0460153A1 (fr) NOUVEAUX $g(b)-CARBOLINES, PROCEDES POUR LEUR FABRICATION ET LEUR UTILISATION DANS DES MEDICAMENTS
US6177569B1 (en) Oxo-pyridoimidazole-carboxamides: GABA brain receptor ligands
JPH01190680A (ja) インドール誘導体およびその製造方法
EP0271040A2 (fr) Pyrrolobenzimidazoles, procédé pour leur préparation, et médicaments
DE3850861T2 (de) Imidazochinoxalinverbindungen und ihre Herstellung und Verwendung.
EP0237467B1 (fr) Dérivés d'hétéroaryl-oxy-bêta-carboline, leur préparation et utilisation comme médicaments
DD254007A5 (de) Verfahren zur herstellung von 3-oxadiazol- und 3-carbonsaeure-ester-beta-carbolinderivaten
EP0557497A1 (fr) Nouveaux derives de la beta-carboline, preparation et utilisation de ces derives dans des medicaments
WO1998003511A1 (fr) Nouvelles triazolopurines, procede pour les preparer et leur utilisation comme medicaments
EP0541757A1 (fr) NOUVELLES HETARYLOXY-$g(b)-CARBOLINES, LEUR FABRICATION ET LEUR UTILISATION DANS DES MEDICAMENTS
EP0543968A1 (fr) 3-ARYL- OU 3-HETARYL-$g(b)-CARBOLINES, LEUR FABRICATION ET LEUR UTILISATION DANS DES MEDICAMENTS
EP0207483B1 (fr) Benzimidazoles, procédé pour leur préparation, médicaments les contenant et intermédiaires
EP0334289B1 (fr) 5,7-Dihydropyrrolo (3,2-f) benzoxazol-6-ones substituées par hétérocycle, procédé pour leur préparation et médicaments les contenant
US5114944A (en) 2-phenylpyrazolo[1,5-a]pyrimidine-3-acetic acid derivatives exhibiting therapeutic effects
EP0240026A1 (fr) Benzoglyoxalines substituées hétérocycliquement, procédé pour leur préparation et médicaments contenant ces composés
EP0268178A1 (fr) Pyrrolo benzimidazoles, médicaments contenant ces composés et leur procédé de préparation
EP0820454B1 (fr) Beta-carbolines annelees

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19921106

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19961112

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19970219